Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827243 | 1.00 | KDM4E (0.49) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1824475 | 0.91 | TSHR (0.53) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1824480 | 0.91 | TSHR (0.53) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1825808 | 0.89 | KDM4E (0.52) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1829017 | 0.89 | KDM4E (0.52) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1825743 | 0.89 | KDM4E (0.49) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1825739 | 0.89 | KDM4E (0.49) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1823989 | 0.85 | ALDH1A1 (0.46) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1823995 | 0.85 | ALDH1A1 (0.46) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1828703 | 0.84 | KMT2A (0.48) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | claimed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | claimed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | claimed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | KDM4E 4207/4885MEN1 1718/4885ALDH1A1 1441/4885 |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | KDM4E 4172/4885MEN1 1752/4885ALDH1A1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.